Literature DB >> 25241302

Prospective, randomized study of coil embolization versus Surefire infusion system during yttrium-90 radioembolization with resin microspheres.

Aaron M Fischman1, Thomas J Ward2, Rahul S Patel2, Aravind Arepally3, Edward Kim2, F Scott Nowakowski2, Robert A Lookstein2.   

Abstract

PURPOSE: To compare standard coil embolization versus the use of an antireflux microcatheter (ARM) in patients undergoing planning angiography before selective internal radiation therapy (SIRT).
MATERIALS AND METHODS: A prospective, single-center trial was performed in which 30 patients were randomly assigned to undergo SIRT with coil embolization or the use of an ARM. The coil group underwent detachable coil embolization of nontarget vessels, and the ARM group underwent infusion of macroaggregated albumin with use of an ARM system, without coil embolization. Single-photon emission computed tomography (CT)/CT was then performed to assess for nontarget distribution. The primary endpoint was fluoroscopy time during planning angiography. Secondary endpoints included deployment time, total procedure time, radiation dose-area product, contrast agent used, and adverse events. Endpoints were evaluated during planning angiography and SIRT.
RESULTS: Over a 9-month period, 30 consecutive patients were randomized at a 1:1 ratio between coil embolization and ARM groups. Technical success rates were 100% in both groups. Mean fluoroscopy time was significantly reduced in the ARM group versus the coil embolization group (1.8 min [range, 0.4-4.9 min] vs 6.0 min [range, 1.9-15.7 min]; P = .002). The planning procedure time (P < .001), deployment time (P < .001), dose-area product (P = .04), and amount of contrast agent used (P < .001) were also significantly less in the ARM group than in the coil embolization group. No nontarget distribution was detected in either group. There was no difference between groups in dose delivered on the day of SIRT (P = .71). There were no major or minor adverse events at 30 days.
CONCLUSIONS: The use of an ARM during planning angiography can significantly reduce fluoroscopy time, procedure time, and radiation dose.
Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25241302     DOI: 10.1016/j.jvir.2014.08.007

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  Surefire infusion system versus standard microcatheter use during holmium-166 radioembolization: study protocol for a randomized controlled trial.

Authors:  Andor F van den Hoven; Jip F Prince; Rutger C G Bruijnen; Helena M Verkooijen; Gerard C Krijger; Marnix G E H Lam; Maurice A A J van den Bosch
Journal:  Trials       Date:  2016-10-25       Impact factor: 2.279

2.  Innovation in catheter design for intra-arterial liver cancer treatments results in favorable particle-fluid dynamics.

Authors:  Andor F van den Hoven; Marnix G E H Lam; Shaphan Jernigan; Maurice A A J van den Bosch; Gregory D Buckner
Journal:  J Exp Clin Cancer Res       Date:  2015-08-01

Review 3.  Radioembolization: Is Prophylactic Embolization of Hepaticoenteric Arteries Necessary? A Systematic Review.

Authors:  Alicia S Borggreve; Anadeijda J E M C Landman; Coco M J Vissers; Charlotte D De Jong; Marnix G E H Lam; Evelyn M Monninkhof; Jip F Prince
Journal:  Cardiovasc Intervent Radiol       Date:  2016-03-02       Impact factor: 2.740

4.  Approaches for safe transarterial chemoembolization of multifocal hepatocellular carcinoma with retrograde flow in a retroportal artery.

Authors:  Souheil Saddekni; Amr Soliman Moustafa; Sherif Moawad; Khalid Mahmoud; Basant Farouk Hamed; Ahmed Kamel Abdel-Aal
Journal:  Radiol Case Rep       Date:  2017-12-01

Review 5.  Gastrodoudenal Embolization: Indications, Technical Pearls, and Outcomes.

Authors:  Gokhan Kuyumcu; Igor Latich; Rulon L Hardman; Gabriel C Fine; Rahmi Oklu; Keith B Quencer
Journal:  J Clin Med       Date:  2018-05-02       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.